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potassium variability and in-hospital mortality in
critically ill patients and a before-after analysis on
the impact of computer-assisted potassium control
Lara Hessels1, Miriam Hoekstra1,2, Lisa J Mijzen1,3, Mathijs Vogelzang1, Wim Dieperink1, Annemieke Oude Lansink1
and Maarten W Nijsten1*Abstract
Introduction: The relationship between potassium regulation and outcome is not known. Our first aim in the
present study was to determine the relationship between potassium level and variability in (ICU) stay and outcome.
The second aim was to evaluate the impact of a computer-assisted potassium regulation protocol.
Methods: We performed a retrospective before-after study including all patients >15 years of age admitted for
more than 24 hours to the ICU of our university teaching hospital between 2002 and 2011. Potassium control was
fully integrated with computerized glucose control (glucose and potassium regulation program for intensive care
patients (GRIP-II)). The potassium metrics that we determined included mean potassium, potassium variability
(defined as the standard deviation of all potassium levels) and percentage of ICU time below and above the reference
range (3.5 through 5.0 mmol/L). These metrics were determined for the first ICU day (early phase) and the subsequent
ICU days (late phase; that is, day 2 to day 7). We also compared potassium metrics and in-hospital mortality before and
after GRIP-II was implemented in 2006.
Results: Of all 22,347 ICU admissions, 10,451 (47%) patients were included. A total of 206,987 potassium measurements
were performed in these patients. Glucose was regulated by GRIP-II in 4,664 (45%) patients. The overall in-hospital
mortality was 22%. There was a U-shaped relationship between the potassium level and in-hospital mortality (P <0.001).
Moreover, potassium variability was independently associated with outcome. After implementation of GRIP-II, in the late
phase the time below 3.5 mmol/L decreased from 9.2% to 3.9% and the time above 5.0 mmol/L decreased from 6.1%
to 5.2%, and potassium variability decreased from 0.31 to 0.26 mmol/L (all P <0.001). The overall decrease in in-hospital
mortality from 23.3% before introduction of GRIP-II to 19.9% afterward (P <0.001) was not related to a specific potassium
subgroup.
Conclusions: Hypokalemia, hyperkalemia and potassium variability were independently associated with increased
mortality. Computerized potassium control clearly resulted in improved potassium metrics.* Correspondence: m.w.n.nijsten@umcg.nl
1Department of Critical Care, University of Groningen, University Medical
Center Groningen, Hanzeplein 1, Groningen 9700 RB, the Netherlands
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Potassium homeostasis is frequently disturbed in critically
ill patients [1]. Underlying diseases or treatments in inten-
sive care unit (ICU) patients often affect the Na+/K+-
ATPase pump. This pump maintains the potassium
gradient and can be influenced by many factors, such as in-
sulin, catecholamine and acid–base status. The long-term
potassium balance is regulated mainly by the kidney. Thus,
dyskalemia is often the result of renal impairment [1,2].
Both hypo- and hyperkalemia are known to induce po-
tentially lethal arrhythmias and cardiac dysfunction, as
well as other complications [1,3,4]. Derangements in
serum potassium levels in ICU patients should therefore
be avoided, and monitoring of potassium is mandatory.
There are surprisingly few data on the relationship be-
tween serum potassium and mortality in ICU patients. A
recent study showed a strong, independent association
between hyperkalemia at the onset of ICU treatment
and in-hospital mortality, even at moderate increases
above the normal range. A causal relation could not be
demonstrated [5].
Our first objective in the present study was to evaluate
the relationship between potassium levels and in-hospital
mortality. In 2006, our ICU introduced a nurse-centered,
computerized potassium regulation protocol integrated
with previously implemented computerized glucose con-
trol. Our secondary objective was to evaluate the impact
of this computerized protocol on potassium control.
Materials and methods
Study population
This retrospective observational cohort study was per-
formed at the adult ICU of our university teaching hos-
pital. This ICU includes three surgical subunits (including
cardiothoracic surgery and neurosurgery) and a medical
subunit, comprising a total of 47 beds. All patients, ages
>15 years who were admitted to the ICU during a 10-year
period (2002 through 2011) were evaluated. In order to as-
sess the role of ICU-acquired potassium derangements,
only patients admitted for at least 24 hours were studied.
If a patient had multiple ICU admissions, the first ICU ad-
mission of the patient’s last hospital admission was used
for analysis.
The anonymized data analysis in this study was per-
formed in accordance with the guidelines and outlined in
Dutch legislation, and the study was approved by the med-
ical ethics committee of our institution (Medisch Ethische
Commissie, UMC Groningen, METc 2014.264). Because
this was a retrospective study of routinely collected data, in-
formed consent was not required by our ethics committee.
Potassium measurements and other parameters
Potassium measurements determined before ICU admis-
sion, as well as samples known to be hemolyzed orotherwise obviously erroneous and thus considered less
reliable, were excluded. For this purpose, the authenti-
city of all potassium measurements ≥7.0 mmol/L and
≤2.0 mmol/L was also separately verified by examin-
ation of patient files. The selected measurements were
verified by scanning the patients’ medical records for
known causes of extreme serum potassium levels, such
as previously diagnosed hypo- or hyperkalemia, renal
dysfunction and cardiopulmonary resuscitation during
the corresponding hospital admission. When no plausible
explanation was found for an extreme measurement and
the measurement represented an isolated high or low
value, preceded and followed by normal values from sam-
ples taken within 2 hours of the abnormal measurement,
this measurement was excluded from further analysis.
Data were obtained from our electronic database and pa-
tient files and included basic demographics, reason for
ICU admission, in-hospital mortality, inclusion in the glu-
cose and potassium regulation program for intensive care
patients (GRIP-II) and hospital follow-up. All potassium
levels (reference range, 3.5 through 5.0 mmol/L) measured
during the patient’s ICU stay, with a maximum of the first
7 days of ICU admission, were collected. A recent recom-
mendation on glucose metrics was used as a guide to de-
cide which potassium values to report [6]. Minimum,
maximum and mean potassium levels, as well as potassium
variability, were determined for every patient. The mini-
mum and maximum potassium levels of the patients were
used to derive the incidence of hypo- and hyperkalemia.
In cases where a patient was both hypokalemic and
hyperkalemic, both values were counted. The potassium
range was defined as the difference between the minimal
and maximal potassium levels. Potassium variability was
defined as the standard deviation (SD) of the potassium
measurements in every patient. The admission serum
potassium level was defined as the first measurement
within 24 hours after ICU admission. Mild hypokalemia
was defined as <3.5 mmol/L to 3.0 mmol/L, and severe
hypokalemia was defined as <3.0 mmol/L. Mild hyperka-
lemia was defined as >5.0 mmol/L to 6.0 mmol/L, and
severe hyperkalemia was defined as >6.0 mmol/L [7].
Potassium levels were measured and recorded in milli-
moles per liter (1 mmol/L = 1 mEq/L).
Disturbances in renal function were defined and staged
according to the Kidney Disease: Improving Global Out-
comes (KDIGO) definition of acute kidney injury (AKI)
[8]. Severity of illness was defined according to the Acute
Physiology and Chronic Health Evaluation II (APACHE II)
score when available. Admission serum glucose was de-
fined as the first glucose measurement within the first
24 hours after ICU admission. In order to assess the rela-
tion of marked admission hyperglycemia with potassium,
hyperglycemia was categorized into 15 to 20 mmol/L and
>20 mmol/L groups.
Table 1 Patient characteristics and blood summary statisticsa
Total (N = 10,451) Survivors (n = 8,175) Nonsurvivors (n = 2,276) P-value
Baseline characteristics
Age, yr, mean (SD) 59.4 (16.7) 58.3 (16.9) 63.3 (15.4) <0.001*
Sex, male, n (%) 6,340 (60.7) 5,007 (61.2) 1,333 (58.6) 0.021
Reason for admission
Medical 2,766 (27.5) 1798 (21.9) 977 (42.9) <0.001
Surgical 7,670 (73.5) 6,372 (78.1) 1,298 (57.1)
Included in GRIP-II 4,664 (44.6) 3,735 (45.7) 929 (40.8) <0.001
LOS ICU, days 4.1 (2.0 to 10.1) 3.8 (2.0 to 9.3) 5.9 (2.9 to 12.8) <0.001*
LOS hospital, days 17.8 (10.1 to 32.0) 19.8 (12.1 to 34.8) 9.9 (4.2 to 21.4) <0.001*
APACHE II scoreb 16 (12 to 21) 15 (11 to 19) 21 (17 to 27) <0.001*
AKIc 3,443 (33.3) 2,162 (26.5) 1,281 (56.3) <0.001
KDIGO stage 1 1,388 (40.3) 1,033 (47.8) 355 (27.8)
KDIGO stage 2 680 (19.8) 432 (20.0) 248 (19.4)
KDIGO stage 3 1,375 (40.0) 697 (31.8) 678 (52.9)
RRT 999 (9.6) 524 (6.4) 475 (20.9) <0.001
Potassium summary statistics, early phased
Admission K+ level, mmol/L 4.1 (3.7 to 4.5) 4.0 (3.7 to 4.4) 4.1 (3.7 to 4.7) <0.001*
K+ measurements, n 6.0 (3.0 to 8.0) 6.0 (3.0 to 8.0) 5.0 (3.0 to 8.0) 0.235*
Mean K+ level, mmol/L 4.2 (3.9 to 4.5) 4.2 (3.9 to 4.5) 4.2 (3.8 to 4.6) 0.025*
K+ variability, mmol/L 0.29 (0.19 to 0.43) 0.28 (0.19 to 0.42) 0.32 (0.21 to 0.50) <0.001*
K+ range, mmol/L 0.70 (0.40 to 1.10) 0.70 (0.40 to 1.10) 0.80 (0.40 to 1.20) <0.001*
Time in hypokalemia, mean SDe 7.4 (21.4) 6.7 (20.7) 9.8 (23.7) <0.001*
Time in hyperkalemia, mean SDe 7.6 (21.5) 6.5 (19.7) 11.4 (26.7) <0.001*
Hypokalemia, mild 1,877 (18.2%) 1,417 (17.6%) 460 (20.3%) 0.003
Hypokalemia, severe 418 (4.0%) 272 (3.4%) 146 (6.5%) <0.001
Hyperkalemia, mild 1,677 (16.2%) 1,218 (15.1%) 459 (20.3%) <0.001
Hyperkalemia, severe 411 (4.0%) 259 (3.2%) 152 (6.7%) <0.001
Potassium summary statistics, late phase
Mean K+ level, mmol/L 4.2 (3.9 to 4.4) 4.1 (3.9 to 4.4) 4.2 (4.0 to 4.6) <0.001*
K+ measurements, n 2.0 (1.0 to 3.9) 1.9 (1.0 to 3.6) 2.2 (1.1 to 4.5) <0.001*
K+ variability, mmol/L 0.28 (0.19 to 0.40) 0.26 (0.17 to 0.37) 0.35 (0.24 to 0.51) <0.001*
K+ range, mmol/L 0.28 (0.03 to 0.50) 0.25 (0.00 to 0.47) 0.36 (0.10 to 0.60) <0.001*
Time in hypokalemia, mean (SD)e 6.4 (17.6) 6.3 (17.8) 6.7 (16.8) <0.001*
Time in hyperkalemia, mean (SD)e 5.7 (17.0) 3.5 (12.8) 13.4 (25.9) <0.001*
Hypokalemia, mild 2,110 (20.2%) 1,597 (19.5%) 513 (22.5%) 0.002
Hypokalemia, severe 345 (3.3%) 237 (2.9%) 108 (4.8%) <0.001
Hyperkalemia, mild 1,733 (17.0%) 1,127 (13.8%) 646 (28.4%) <0.001
Hyperkalemia, severe 375 (3.6%) 140 (1.7%) 235 (10.3%) <0.001
aGRIP-II, Glucose and potassium regulation program for intensive care patients; LOS, Length of stay; RRT, Renal replacement therapy; SD, Standard deviation.
Values are expressed as number (%) or median (interquartile range) unless otherwise specified. Statistical analysis was performed by using a χ2 test, unless marked
by an asterisk, in which case a Mann–Whitney U test was used. bAcute Physiology and Chronic Health Evaluation II (APACHE II) scores were available for 5,294
(50.7%) patients. cAcute kidney injury (AKI) severity was defined on the basis of the Acute Kidney Injury Network’s Kidney Disease: Improving Global Outcomes
(KDIGO) criteria [8]. There were no data available for 6 (0.06%) patients. dPotassium levels during the first 24 hours were known for 10,327 (98.8%) patients.
ePercentage of total intensive care unit (ICU) stay. Nonsurvivors and survivors differed significantly from each other. Nonsurvivors had more potassium
derangements and a higher potassium variability.
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A nurse-centered, computerized potassium regulation
protocol called glucose and potassium regulation in in-
tensive care patients (GRIP) has been fully operational at
our ICU for several years. This protocol was first imple-
mented as a glucose regulation system (GRIP-I), but a
potassium algorithm was successfully integrated later
(GRIP-II). GRIP-II provides advice about the desired rate
of potassium administration and the time interval until
the next potassium measurement after analysis of a
blood sample. All recommendations made by GRIP-II can
be overruled or adjusted by a nurse or physician at any
time, and all were automatically recorded. The potassium
target range was set in the middle of the normal range
(that is, 4.3 mmol/L), similar to the potassium targetFigure 1 Lowest and highest potassium levels and outcomes in
the early and late phases of intensive care unit admission.
Relationship between abnormal potassium levels and mortality
during the first 24 hours of intensive care unit (ICU) admission (early
phase; upper panel) and days 2 through 7 (late phase; lower panel)
of ICU admission. This distinction was made because the initial
derangements often cannot be influenced by ICU treatment. Both
the lowest and the highest potassium levels measured during the
relevant episode were used. Lower and higher potassium levels
were both associated with a marked increase in mortality risk. The
incidences are indicated above the x-axis. Thus, 59% and 60% of the
patients had neither hypokalemia nor hyperkalemia in the early and
late phases, respectively. Because some patients are represented in
both a hypokalemic and a hyperkalemic category, the percentages
add up to more than 100%.before implementation of this computerized protocol. More
detailed descriptions of the design and implementation of
this system have been published previously [9,10].
Endpoints
The primary endpoint of this study was in-hospital mor-
tality. The secondary endpoint was the effect of GRIP-II
on potassium control.
Statistical analysis
All potassium measurements were split into an early phase
(first ICU day) and late phase (ICU days 2 through 7) for
both the whole patient cohort and divided according to
the regulation of GRIP-II. Baseline demographics and
blood potassium levels were compared between survivors
and nonsurvivors and before and after GRIP-II using con-
tingency tables and the χ2 test. The categorization of pa-
tients by regulation of serum potassium levels by GRIP-II
was made by conducting an intention-to-treat analysis.
Logistic multivariate regression analysis was performed
to assess the independent relationship between the ob-
tained variables and in-hospital mortality. The regression
analysis was corrected for sex, age, severity of illness,
AKI, mean potassium, mean potassium squared and po-
tassium variability. A two-sided P-value of 0.05 was con-
sidered significant. Data reduction and statistical analysis
were performed with SPSS version 22 software (IBM
SPSS, Chicago, IL, USA).
Results
During the study period, a total of 22,347 patients were
admitted to our ICU, and they had a total of 256,410
serum potassium measurements. Of these potassium mea-
surements, 256,200 (99.9%) were assessed as realistic.Figure 2 Relationship of mean potassium level and potassium
variability with mortality. The relationship between mean
potassium and mortality is depicted for five quintiles (black curve).
For each mean potassium quintile, quartiles of potassium variability
(colored bars) are shown.
Table 2 Potassium variability quartiles used for each mean potassium quintile shown in Figure 2
Mean potassium concentration (mmol/L) Quartile 1 Quartile 2 Quartile 3 Quartile 4
<3.86 (n = 2,089) <0.17 0.17 to 0.26 0.26 to 0.38 >0.38
3.86 to 4.06 (n = 2,089) <0.18 0.18 to 0.26 0.26 to 0.37 >0.37
4.06 to 4.24 (n = 2,111) <0.19 0.19 to 0.28 0.28 to 0.38 >0.38
4.24 to 4.48 (n = 2,080) <0.19 0.19 to 0.28 0.28 to 0.40 >0.40
>4.48 (n = 2,082) <0.21 0.21 to 0.33 0.33 to 0.51 >0.51
Total = 10,451
Table 3 Multivariate analysis for hospital mortalitya
OR (95% CI) P-value
Model 1
Sex, female 1.08 (0.97 to 1.20) 0.159
Age 1.018 (1.014 to 1.021) <0.001
Mean potassium 0.002 (0.000 to 0.008) <0.001
Mean potassium squared 2.18 (1.85 to 2.57) <0.001
Potassium variability 9.37 (7.25 to 12.10) <0.001
Model 2
Sex, female 1.12 (1.01 to 1.25) 0.032
Age 1.017 (1.013 to 1.020) <0.001
AKI 2.50 (2.25 to 2.79) <0.001
Mean potassium 0.003 (0.001 to 0.013) <0.001
Mean potassium squared 2.02 (1.71 to 2.38) <0.001
Potassium variability 5.83 (4.49 to 7.58) <0.001
Model 3
Sex, female 1.22 (1.05 to 1.42) 0.012
Age 1.008 (1.003 to 1.013) 0.002
APACHE II score 1.104 (1.091 to 1.116) <0.001
AKI 1.76 (1.50 to 2.06) <0.001
Mean potassium 0.008 (0.001 to 0.082) <0.001
Mean potassium squared 1.84 (1.40 to 2.41) <0.001
Potassium variability 5.61 (3.64 to 8.66) <0.001
aCI, Confidence interval; OR, Odds ratio. Data are adjusted for sex, age, acute kidney
injury (AKI), severity of illness (Acute Physiology and Chronic Health Evaluation II
(APACHE II) score), mean potassium, mean potassium squared and potassium
variability observed between 24 hours and 7 days after admission. For all variables
except potassium variability (9,228 patients (88%)) and APACHE II score (4,883
patients (51%)), virtually complete data were available, therefore the multivariate
analysis was performed with APACHE II score (lower panel) and without APACHE II
score. In-hospital mortality was associated with all domains of potassium control. In
order to test for a U-shaped relationship of mean potassium with hospital mortality,
the mean potassium concentration was both included directly and squared.
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of 206,987 serum potassium measurements who were ad-
mitted to our ICU for more than 24 hours. The data gath-
ered during the first 24 hours of the ICU stay were available
for 10,327 patients (98.8%). The minimum and maximum
serum potassium levels observed were 1.5 mmol/L and
10.8 mmol/L, respectively. The baseline characteristics of
the 10,451 patients studied are shown in Table 1. AKI oc-
curred in 3,443 (33.3%) of the patients. A total of 999 (9.6%)
patients received renal replacement therapy (RRT).
Abnormal serum potassium levels and in-hospital mortality
The in-hospital mortality number was 2,276 (21.8%), and ad-
mission potassium levels were higher in patients who died
during their hospital stay than among patients who survived.
It should be stressed that all the incidences mentioned refer
to the number of patients with potassium derangements,
not to the number of deranged measurements. There was a
U-shaped relationship between potassium levels and in-
hospital mortality (P <0.001) (Figure 1). Potassium variability
was independently related to outcome. The independent im-
pact of variability is given in Figure 2, which shows mean
potassium in quintiles and potassium variability in quartiles
within each quintile (Table 2). Figure 2 shows evidence of
lower in-hospital mortality associated with the lower normal
range for potassium, as well as lower mortality associated
with lower variability across all quintiles. Overall, we saw a
lower potassium variability in survivors in both the early and
late phases (P <0.001). The design of Figure 2 was copied as
faithfully as possible from a figure reported by Krinsley [11]
that depicted a very similar phenomenon for mean glucose
and glucose variability. Multivariate analysis showed an inde-
pendent association with in-hospital mortality for the occur-
rence of both hypokalemia and hyperkalemia and potassium
variability with and without inclusion of APACHE II and
AKI data (Table 3).
Time in hypo- and hyperkalemia was higher for non-
survivors for both the early and late phases (P <0.001)
(Table 1). Time in hypo- and hyperkalemia was noted as
a mean percentage of the total ICU stay and not as a
median percentage, because the medians were 0%. Both
mild and severe hypokalemia occurred more often in
nonsurvivors than in survivors, during both the early
phase and the late phase. The incidence of mild and se-
vere hyperkalemia was also higher in nonsurvivors.Abnormal serum potassium levels and in-hospital mortality
before and after GRIP-II
A total of 4,664 (44.6%) patients were included in GRIP-II.
The baseline patient characteristics before and after the
introduction of GRIP-II are shown in Table 4. The mean
ages (SD) before and after GRIP-II were 59 ± 17 years and
60 ± 16 years, respectively, and 60% and 62% of patients in
these two groups, respectively, were male. After imple-
mentation of GRIP-II, the number of potassium
Table 4 Baseline characteristics and blood potassium summary statistics before and after introduction of GRIP-IIa















Age, yr, mean (SD) 58.6 (17.1) 57.3 (17.3) 62.6 (15.7) <0.001* 60.4 (16.2) 59.4 (16.4) 64.2 (14.8) <0.001* <0.001
Sex, male 3,453 (59.7) 2,652 (59.7) 801 (59.5) 0.863 2,887 (61.9) 2,355 (63.1) 532 (57.3) 0.001 0.020
Reason for admission
Medical 1,979 (34.3) 1,270 (28.7) 709 (52.6) <0.001 787 (16.9) 519 (13.9) 268 (28.9) <0.001 <0.001
Surgical 3,799 (65.7) 3,161 (71.3) 638 (47.4) <0.001 3,871 (83.1) 3,211 (86.1) 660 (71.1) <0.001 <0.001
LOS ICU, days 4.2 (21. to 10.0) 3.9 (2.0 to 9.0) 5.8 (2.9 to 12.3) <0.001* 4.0 (2.0 to 10.5) 3.8 (1.9 to 9.7) 6.1 (3.0 to 13.4) <0.001* 0.194*
LOS hospital, days 17.5 (9.9 to 18.3) 19.8 (12.1 to 35.1) 9.3 (4.1 to 20.1) <0.001* 18.1 (10.3 to 32.5) 19.8 (12.2 to 34.5) 10.3 (4.3 to 23.7) <0.001* 0.005*
APACHE II scorec 17 (12 to 22) 15 (11 to 20) 21 (17 to 28) <0.001* 16 (12 to 21) 15 (11 to 19) 21 (17 to 27) <0.001* 0.222*
AKId 1,934 (33.4) 1,174 (26.5) 760 (56.4) <0.001 1,509 (32.3) 988 (26.4) 521 (56.1) <0.001 0.384
KDIGO stage 1 767 (39.7) 551 (47.0) 216 (28.4) 621 (41.2) 482 (48.8) 139 (26.7)
KDIGO stage 2 376 (19.4) 229 (19.5) 147 (19.3) 304 (20.1) 203 (20.5) 101 (19.4)
KDIGO stage 3 791 (40.9) 394 (33.5) 397 (52.2) 584 (38.7) 303 (30.7) 281 (53.9)
RRT 564 (9.7) 299 (6.7) 265 (19.7) <0.001 435 (9.3) 225 (6.0) 210 (22.6) <0.001 0.466
K+ measurements/day, n 1.7 (1.1 to 3.0) 1.7 (1.1 to 3.1) 1.6 (1.0 to 2.8) 0.003* 5.5 (3.5 to 7.3) 5.4 (3.6 to 7.2) 5.6 (3.0 to 8.1) 0.032* <0.001*
Potassium summary statistics, early phasee
Admission K+ level, mmol/L 4.1 (3.7 to 4.5) 4.1 (3.7 to 4.5) 4.2 (3.7 to 4.7) <0.001* 4.0 (3.7 to 4.4) 4.0 (3.7 to 4.4) 4.1 (3.7 to 4.6) 0.001* <0.001*
Mean K+ level, mmol/L 4.1 (3.8 to 4.5) 4.1 (3.8 to 4.5) 4.2 (3.8 to 4.7) <0.004* 4.2 (3.9 to 4.5) 4.2 (3.9 to 4.4) 4.2 (3.8 to 4.5) 0.935* 0.007*
K+ variability, mmol/L 0.30 (0.17 to 0.47) 0.29 (0.16 to 0.45) 0.33 (0.18 to 0.53) <0.001* 0.29 (0.20 to 0.40) 0.28 (0.19 to 0.39) 0.32 (0.22 to 0.45) <0.001* 0.105*
K+ range, mmol/L 0.50 (0.20 to 1.00) 0.5 (0.20 to 0.90) 0.6 (0.30 to 1.1) <0.001* 0.80 (0.60 to 1.20) 0.8 (0.60 to 1.20) 0.9 (0.70 to 1.40) <0.001* <0.001*
Time in hypokalemia, mean (SD)f 8.9 (25.3) 8.2 (24.6) 11.0 (25.3) <0.001* 5.5 (15.0) 4.9 (14.4) 8.0 (16.9) <0.001* <0.001*
Time in hyperkalemia, mean (SD)f 8.1 (23.3) 6.8 (21.3) 12.0 (28.5) <0.001* 7.0 (19.0) 6.1 (17.6) 10.5 (23.8) <0.001* <0.001*
Hypokalemia, mild 964 (16.9%) 772 (16.5%) 242 (18.0%) 0.201 913 (19.8%) 695 (18.8%) 218 (23.7%) 0.001 <0.001
Hypokalemia, severe 226 (4.0%) 147 (3.4%) 79 (5.9%) <0.001 192 (4.2%) 125 (3.4%) 67 (7.3%) <0.001 0.590
Hyperkalemia, mild 850 (14.9%) 612 (14.0%) 238 (17.7%) 0.001 827 (17.9%) 606 (16.4%) 221 (24.1%) <0.001 <0.001










Table 4 Baseline characteristics and blood potassium summary statistics before and after introduction of GRIP-IIa (Continued)
Potassium summary statistics, late phase
Mean K+ level, mmol/L 4.1 (3.8 to 4.4) 4.1 (3.8 to 4.3) 4.2 (3.9 to 4.6) <0.001* 4.2 (4.0 to 4.4) 4.2 (4.0 to 4.4) 4.3 (4.1 to 4.6) <0.001* <0.001*
K+ variability, mmol/L 0.31 (0.20 to 0.46) 0.29 (0.19 to 0.42) 0.38 (0.25 to 0.55) <0.001* 0.26 (0.18 to 0.35) 0.24 (0.17 to 0.32) 0.33 (0.23 to 0.44) <0.001* <0.001*
K+ range, mmol/L 0.10 (0.00 to 0.33) 0.1 (0.00 to 0.30) 0.18 (0.00 to 0.4) <0.001* 0.43 (0.30 to 60) 0.40 (0.25 to 0.57) 0.55 (0.4 to 0.75) <0.001* <0.001*
Time in hypokalemia, mean (SD)f 9.2 (20.9) 9.1 (21.4) 9.3 (19.4) <0.001* 3.0 (11.3) 3.0 (11.4) 3.0 (10.7) 0.060* <0.001*
Time in hyperkalemia, mean (SD)f 6.1 (18.2) 3.7 (13.6) 13.9 (27.2) <0.001* 5.2 (15.5) 2.2 (11.8) 12.7 (23.9) <0.001* <0.001*
Hypokalemia, mild 1,346 (23.3%) 998 (22.5%) 348 (25.8%) 0.011 764 (16.4%) 599 (16.0%) 165 (17.8%) 0.204 <0.001
Hypokalemia, severe 241 (4.2%) 162 (3.6%) 79 (5.9%) <0.001 104 (2.2%) 75 (2.0%) 29 (3.2%) 0.040 <0.001
Hyperkalemia, mild 867 (15.0%) 541 (12.2%) 326 (24.2%) <0.001 906 (19.4%) 586 (15.7%) 320 (34.4%) <0.001 <0.001
Hyperkalemia, severe 207 (3.6%) 72 (1.7%) 135 (10.0%) <0.001 168 (3.6%) 68 (1.8%) 100 (10.7%) <0.001 0.945
aLOS, Length of stay; RRT, Renal replacement therapy. Data are expressed as number (%) or median (interquartile range) unless otherwise specified. Statistical analysis was performed by using a χ2 test, unless marked
by an asterisk, in which case a Mann–Whitney U test was used. bBefore and after glucose and potassium regulation program for intensive care patients (GRIP-II) comparison. cAcute Physiology and Chronic Health
Evaluation II (APACHE II) scores were known for 5,294 (50.7%) patients. dAcute kidney injury (AKI) was defined according to the Acute Kidney Injury Network’s Kidney Disease: Improving Global Outcomes (KDIGO)
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(IQR), 1.1 to 3.0) per patient per day to 5.5 (IQR, 3.5 to
7.3) measurements per patient per day (P <0.001). The oc-
currence of AKI, as well the use of RRT, did not differ be-
fore and after the implementation of GRIP-II. More
patients with AKI developed mild and severe hyperkale-
mia (Table 5). Also, patients with marked hyperglycemia
at admission more frequently developed hyperkalemia
than patients with normoglycemia (Table 6). The overall
in-hospital mortality decreased from 1,347 (23.3%) to 929
(19.9%) after implementation of GRIP-II (Table 4). The
U-shaped relationship between potassium extremes and
mortality persisted after the introduction of GRIP-II
(Figure 3).
Potassium variability was significantly less in patients
regulated by GRIP-II during the late phase (Table 4),
despite an increase of the potassium range after GRIP-II
(P <0.001). The time in hypo- and hyperkalemia was less
in both phases for patients regulated by GRIP-II, but this
improvement was particularly visible after 24 hours in
survivors for the time in hypokalemia.
Late mild as well severe hypokalemia decreased in pa-
tients who were regulated by GRIP-II. Mild hyperkale-
mia, on the other hand, increased after implementation
of GRIP-II. Severe hyperkalemia did not differ before and
after implementation of GRIP-II.
Discussion
In this first study to comprehensively address the relation-
ship of potassium concentration with outcome in the ICU,
we show a strong relationship between potassium levels
and potassium variability with in-hospital mortality, which
persisted after adjustment for disease severity and AKI.
After implementation of a novel computer-guided potas-
sium algorithm, improvement of hypokalemia, hyperkale-
mia and potassium variability was observed.
The effect of our computerized regulation protocol
was particularly visible during the late phase (that is,
after the first 24 hours of the ICU stay). This observation
underscores the fact that GRIP-II cannot affect the po-
tassium levels that patients have upon admission to the
ICU, a time when abnormal laboratory values are par-
ticularly prevalent. Thus, GRIP-II required some time to









Normokalemia 4,637 (81.2) 3,330 (87.9) 1,307 (67.9) <0.00
Hyperkalemia, mild 850 (14.9) 405 (10.7) 445 (23.1) <0.00
Hyperkalemia, severe 227 (4.0) 54 (1.4) 173 (9.0) <0.00
aData are expressed as number (%) unless otherwise specified. Statistical analysis w
regulation program for intensive care patients (GRIP-II) comparison.Although the relationship of abnormal potassium levels
and potassium variability with in-hospital mortality per-
sisted, computerized control managed to get more pa-
tients within the normal range. For those patients who
still had deranged potassium levels, the mortality rate was
not higher after GRIP-II than before GRIP-II. Our present
retrospective study, which covered a large period that saw
important changes in critical care treatment, obviously
does not allow us to draw any definite conclusions on a
potential beneficial mortality effect of GRIP-II, but at the
least it suggests that stricter potassium control is feasible.
In contrast to a large recent observational study on the
relationship between potassium and outcome [5], we took
into account both sides of potassium derangements, find-
ing an increased mortality rate in both hypo- and hyperka-
lemia. Hypo- and hyperkalemia are associated with an
increased risk of potentially fatal complications. Both ei-
ther should be avoided in critically ill patients or should
be rapidly corrected when severely deranged [1-4,7]. The
precise mechanisms that relate in-hospital mortality and
potassium are not known. It has been proposed that mild
abnormalities could be a marker of disease, whereas
severe potassium derangements could be a cause of mor-
tality [5]. Mild hypo- and hyperkalemia are often asymp-
tomatic. Cardiac dysfunction is frequently caused by
worse abnormalities.
That the multivariate relationships of both mean
potassium and potassium variability with mortality
(Figure 2, Table 2) were as marked as those observed by
others for glucose [11] could be explained in at least two
ways. One explanation could be that potassium variabil-
ity has a direct causal relationship with outcome, such
as through rapidly changing conditions in the cell mem-
brane. A second explanation could be that a higher po-
tassium variability, or, for that matter, variability of many
other parameters, may be a marker of patient instability
in general. Recently, it was reported that fluctuations in
sodium were also associated with outcome [12]. Until
more mechanistic data are available, we believe the sec-
ond, noncausal explanation is more appropriate. Regard-
less of whether it may be useful, the GRIP system was
able to decrease potassium variability.
Integration of GRIP-II into our ICU workflow was well









1 3,598 (78.1) 2,691 (86.5) 907 (60.5) <0.001 <0.001
1 827 (17.9) 367 (11.8) 460 (30.7) <0.001 0.098
1 184 (4.0) 52 (1.7) 132 (8.8) <0.001 0.179
as performed by using a χ2 test. bBefore and after glucose and potassium
Table 6 Relationship between hyperkalemia and admission hyperglycemia before and after GRIP-IIa


















Normokalemia 4,639 (81.2) 4,410 (81.8) 163 (73.4) 66 (64.7) <0.001 3,600 (78.1) 3,365 (79.1) 187 (69.5) 48 (53.3) <0.001 <0.001
Hyperkalemia, mild 850 (14.9) 778 (14.4) 43 (19.4) 29 (28.4) 0.012 827 (17.9) 718 (17.1) 66 (24.5) 33 (36.7) 0.003 0.040
Hyperkalemia, severe 227 (4.0) 204 (3.8) 16 (7.2) 7 (6.9) <0.001 184 (4.0) 159 (3.7) 16 (5.9) 9 (10.0) <0.001 0.511










Figure 3 Relationship between lowest and highest potassium
level and outcome during before and after glucose and
potassium regulation program for intensive care patients
(GRIP-II). Analogously to Figure 1, here mortality is depicted as a
function of abnormal potassium values observed during the early
phase (upper panel) and the late phase (lower panel). Patients
treated before GRIP-II are shown in black and with GRIP-II in red.
Note that, in contrast to the early phase, mortality in the late phase
is either comparable or lower in the GRIP-II group across the
potassium range.
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control protocol, it did not add any significant nursing
time or costs [10]. We consider it a good example of non-
critical tasks being successfully delegated to nurses and
being computerized. To our knowledge, no other ICUs
have yet incorporated GRIP-II, despite its being freely
available on the internet. GRIP-II currently operates inde-
pendently of a Patient Data Management System (PDMS),
but the algorithm can also be incorporated into a PDMS.
Despite safely reducing the number of patients with hypo-
kalemia and reducing time in hypokalemia and time in
hyperkalemia, GRIP-II caused a mild increase in moderate
hyperkalemia. Preventing hyperkalemia and hypokalemia
through GRIP-II was achieved only by regulating potas-
sium infusion, because other actions to change potassium
levels could be prescribed only by the intensivist. Thus,
in cases of (impending) hyperkalemia, GRIP-II can only
discontinue the potassium infusion. We assumed that
this mechanism caused a higher incidence of patients
with mild hyperkalemia post-GRIP, although the time inhyperkalemia decreased (Table 4). On the basis of these
results, we have recently adjusted the GRIP-II target
downwards slightly, from 4.3 mmol/L (in the middle of
the 3.5 to 5.0 reference range) to 4.0 mmol/L.
The precise optimal range for desired potassium levels
remains unknown. This has been studied in different pa-
tient cohorts, varying between 3.5 and 4.5 mmol/L [13],
4.0 and 5.0 mmol/L [14] or even 4.5 and 5.5 mmol/L in
acute myocardial infarction and HF patients [15], with
no consensus reached. Currently, 3.5 to 5.0 mmol/L is
accepted as a safe range for ICU patients. Whether cut-
off points for potassium should be more precise and
could affect outcome is still unclear.
If deemed sufficiently relevant, a large prospective trial
would be required to address these unanswered ques-
tions. For example, the researchers in the Normogly-
cemia in Intensive Care Evaluation and Survival Using
Glucose Algorithm Regulation (NICE-SUGAR) study,
investigated glucose control in a multicenter trial with
over 6,000 patients [16].
Our study has several important limitations. A key
limitation of our study is its retrospective design, so any
conclusions regarding a causal effect of GRIP-II on out-
come would be inappropriate. The before-after design
introduces many forms of bias, in particular because
many aspects of critical care have changed over the ob-
servation period, as underscored by the differences in
baseline characteristics. The greatest before-after differ-
ence was the greater number of potassium measure-
ments in patients controlled by GRIP-II, which will have
affected metrics. But irrespective of the before-after
character of our study, the obvious impact of close po-
tassium monitoring by GRIP-II on the quality of regula-
tion itself cannot be denied. We think that a potential
future randomized study will be appropriate only when
two computer-guided protocols are compared, as in our
GRIP-COMPASS study [17], in which we compared the
effect of two different computer-guided targets on atrial
fibrillation after cardiac surgery.
Our potassium metrics were derived from studies on
glycemic control. We considered only potassium, sex,
age, severity of illness, renal function, hyperglycemia and
in-hospital mortality. We also did not have APACHE II
scores for an important early part of the cohort. Like-
wise, we did not have the access to trustworthy data
about the use of drugs that could influence potassium
regulation. Therefore, we were not able to take these fac-
tors into consideration.
Conclusions
In a study unique for its scope and size, we found a clear,
U-shaped relationship between early and late potassium
levels and outcome. Potassium variability had a statistically
independent relationship with outcome. Whether a causal
Hessels et al. Critical Care  (2015) 19:4 Page 11 of 11relationship of variability with outcome exists is question-
able. Implementation of GRIP-II led to a decrease in po-
tassium derangements. More stringent potassium control
and decreased potassium variability could influence out-
come, although such an effect can be proven only in a
large prospective study.
Key messages
 For the first time, the relationship of hypokalemia,
hyperkalemia and potassium variability with
outcome was studied in a large, heterogeneous
group of ICU patients.
 Potassium and potassium variability were strongly
and independently related to outcome, similar to
what has been observed for glucose.
 With the open-source GRIP-II program, potassium
control was integrated with glucose control.
 GRIP-II reduced time in hypokalemia, time in
hyperkalemia and potassium variability.
 Apart from the obvious practical benefits of
combined computerized potassium and glucose
control, it is not clear if better potassium control
improves outcome.
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